J Thromb Haemost

• 

  Publication Venue For

  • Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more..  17:2089-2098. 2019
  • Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation..  17:1989-1994. 2019
  • Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy?.  17:1973-1978. 2019
  • The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia..  17:1956-1965. 2019
  • Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy. 2019
  • Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation..  17:1265-1268. 2019
  • A unique protein kinase C-dependent pathway for tissue factor downregulation in pericytes..  17:670-680. 2019
  • Derangement of the endothelial glycocalyx in sepsis..  17:283-294. 2019
  • Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH..  17:415-419. 2019
  • Laboratory criteria for antiphospholipid syndrome: reply..  16:2117-2119. 2018
  • The next best thing in factor VIIa..  16:1911-1913. 2018
  • Use of factor concentrates for the management of perioperative bleeding: reply..  16:2113-2115. 2018
  • Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity..  16:1817-1829. 2018
  • Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study..  16:1069-1077. 2018
  • Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency..  16:849-857. 2018
  • Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH..  16:809-813. 2018
  • Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis..  16:262-270. 2018
  • Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis..  16:231-241. 2018
  • Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers..  16:54-64. 2018
  • Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH..  16:170-174. 2018
  • Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis..  15:1913-1922. 2017
  • A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release..  15:1807-1817. 2017
  • Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis..  15:1322-1333. 2017
  • The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran..  15:1317-1321. 2017
  • The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery..  15:57-65. 2017
  • To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment..  14:2556-2559. 2016
  • An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model..  14:1249-1254. 2016
  • Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery..  14:875-885. 2016
  • When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH..  14:623-627. 2016
  • Actions of thrombin in the interstitium..  14:40-47. 2016
  • Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings..  13:1597-1605. 2015
  • Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages..  13:1416-1427. 2015
  • Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis..  13:1010-1018. 2015
  • Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study..  13:1028-1035. 2015
  • Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome..  13:398-408. 2015
  • Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers..  12:1428-1436. 2014
  • D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial..  12:1401-1412. 2014
  • Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH..  12:792-795. 2014
  • Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH..  11:1593-1596. 2013
  • Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer..  11:1364-1373. 2013
  • Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels..  11:1043-1052. 2013
  • Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study..  11:1194-1197. 2013
  • Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis..  10:2599-2601. 2012
  • Mechanisms and monitoring of bypassing agent therapy..  10:1478-1485. 2012
  • A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent..  10:1303-1311. 2012
  • A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins..  10:1446-1449. 2012
  • Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis..  10:1242-1251. 2012
  • A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity..  10:870-880. 2012
  • Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE..  10:822-832. 2012
  • Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy..  10:692-694. 2012
  • High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low?.  10:487-489. 2012
  • Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis..  9:1902-1915. 2011
  • Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses..  9:1730-1737. 2011
  • Obstetric hemorrhage..  9:1441-1451. 2011
  • Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity..  9:759-766. 2011
  • The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion..  8:2642-2650. 2010
  • Inflammation does not predispose to bleeding in hemophilia..  8:2583-2585. 2010
  • Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis..  8:148-156. 2010
  • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients..  8:43-53. 2010
  • Platelet functions beyond hemostasis..  7:1759-1766. 2009
  • Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis..  7:1737-1740. 2009
  • Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT)..  7 Suppl 1:249-252. 2009
  • The evolution of platelet-directed pharmacotherapy..  7 Suppl 1:266-271. 2009
  • Optimization of a murine immunization model for study of PF4/heparin antibodies..  7:857-864. 2009
  • Endothelial cell junctions and the regulation of vascular permeability and leukocyte transmigration..  6:1453-1460. 2008
  • A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor..  6:789-796. 2008
  • A modified recombinant factor VIIa: can we make it work harder, better, faster, stronger?.  7:1514-1516. 2009